Swift Biosciences is a fast-moving company focused on developing enabling technologies and products for genomics and personalized medicine. Its technologies provide customers with powerful new methods to examine disease-related genes.
Swift Biosciences – genomics and personalized medicine
Swift Biosciences is a fast-moving company focused on developing enabling technologies and products for genomics and personalized medicine. Its proprietary technologies provide customers with powerful new methods to examine disease-related genes. Swift Biosciences’ products are designed to help customers analyze samples faster, easier and with greater sensitivity and accuracy, while being compatible with existing instrumentation. Swift Biosciences is developing products with applications in many areas, including qPCR (myT Primers). myT Primers is a line of novel qPCR reagents that provide both high sensitivity and specificity in mutation detection, ideal for cancer research and diagnostic applications. myT Primers can be used in conventional qPCR machines using standard, single tube protocols. myT Primers work well on both FFPE and fresh frozen specimens, but are also capable of sensitive detection when the sample material is limiting or where the target is present at very low concentration, such as with circulating tumor cells (CTCs), serum, plasma and needle biopsies. Swift has developed myT Primers for the common mutations in BRAF and KRAS genes to demonstrate the superior performance capabilities of the technology for mutation detection. However, the technology is readily applicable to other mutations and infectious disease testing. Furthermore, Swift Biosciences is also developing a suite of differentiated technologies to improve next generation sequencing (NGS) sample preparation. These technologies are based on proprietary protocols and reagents.
Swift Biosciences’ executive team has a strong track record of creating, marketing and selling products that are well regarded by the industry and customers alike. Management Team is composed by Timothy Harkins, Vladimir Makarov and Eric Halverson. Board of Directors is composed by Peter Kleinhenz, Vladimir Makarov, Jack Ball, Dan Watkins and Walter Young. The company was created with the support of experienced life science investors and opened its doors in February 2010. Its multiple innovation platforms have been developed “in house” by a growing team of talented scientists and are covered by multiple patent applications. Swift Biosciences is now working with multiple partners to bring its products to customers, and additional partnering and licensing opportunities are possible.
More about Swift Biosciences : http://www.swiftbiosci.com/